

Single Drug Assessments in Lung Cancer



Published SDA in Lung Cancer 2011 - July 2022

Total number of SDA in Lung cancer



591


published
SDA
2011- July 2022



94

highest
yearly number
of assessments
in 2019

Outcomes




46% Positive
28% Conditional
26% Negative

SDA in Lung cancer EU4 + UK

- 47% of all SDAs are published by the countries in EU4 and UK
- 49% of all assessments in EU4 countries and UK were positive; 23% negative and 28% gained conditional decisions
- Germany being the most restrictive one with 44% of the SDA were rated no added benefit

EU4 + UK



99


SDAs



in UK

2011 - July 2022

**Positive decisions
in EU4 + UK**



Top 5 challenges expressed by all HTA bodies



Clinical

- Immature data
- Increased risk of adverse events
- Not providing relevant data against appropriate comparator
- Not providing efficacy data for the target subgroup
- Indirect treatment comparison not well conducted



Economic

- Not cost effective
- Treatment cost
- Estimate of relevant treatment cost questionable
- Model assumption not justified
- Sources for model parameters questionable

Contact us and request a trial access

hta-accelerator@iqvia.com

Source: IQVIA HTA Accelerator. | All SDAs from January 2011 till July 2022 are included. | This analysis includes only reports with clear positive, restricted/conditioned or negative recommendations; Positive recommendation = The technology has been recommended without any restrictions to the full licensed indication. Restricted/Conditioned = The technology has been recommended but with restrictions to specific patient populations; Negative recommendation = The technology has not been recommended

Abbreviations: HTA = Health technology assessment; SDA = Single drug assessment;